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Umbilical cord blood (UCB) is an alternative graft source for
hematopoietic stem cell transplantation and has been shown
to yield results comparable to transplantation with other
stem cell sources. Donor lymphocyte infusion (DLI) is an
effective treatment for relapsed hematological malignancies
after hematopoietic stem cell transplantation. However, DLI
is not available after UCB transplantation.
In this study, in vitro cultured T-cells from the UCB graft
were explored as an alternative to conventional DLI. The
main aim was to study the safety of treatment with the
cultured UCB T-cells, as cell products prepared in this
particular manner has not been used before. We also wanted
to study potential beneﬁts of the treatment.
The cultured UCB T cells (UCB DLI) were given to four
patients with mixed chimerism (n ¼ 2), minimal residual
disease (n ¼ 1) and graft failure (n¼ 1). No adverse reactions
were seen at transfusion. Graft-versus-host disease (GVHD)
is a known risk in conventional DLI treatment. We thus
carefully assessed the included patients for signs of GVHD.
Three of the patients did not show any signs of GVHD after
treatment with UCB DLI. However, GVHD could not bewholly
excluded in the last patient. The symptoms were, however,
not consistently in temporal association with the treatment,
and the patient also had a severe adenovirus infection that
could explain the symptoms. In the patient with minimal
residual disease, the malignant cell clone was detectable
shortly before infusion but undetectable at treatment and for
3 months after infusion. In one patient with mixed chi-
merism, the percentage of recipient cells decreased in tem-
poral association with UCB DLI treatment.
In summary, we saw no certain adverse effects of
treatment with UCB DLI. Events that could indicate possible
beneﬁts were seen but with no certain causal association
with the treatment.171
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Introduction: Decidual stromalcells (DSCs) isolated fromfetal
membranes of term placentas are easily expanded and highly
immunosuppressive in vitro. DSCs have a high expression ofintegrins that are of importance for homing to damaged tissue.
In thepresent study,we introduceDSCsasa cellular therapy for
chronic Graft-versus-Host Disease (cGvHD).
Patients and Methods: Three patients (1 (ALL), 2 (AML), and
3 (CML)) with severe extensive cGvHD were treated with
DSCs (1-2.8 x 106 cells/kg). Patients 1 and 2 received two
infusions and patient 3 received one dose. One third of DSCs
administered to patient 1 and 2 were labelled with 111Indium
and the in vivo-distribution was tracked for 48h. Blood
samples were obtained before and up to 4-10 weeks after the
ﬁrst infusion. Samples were analyzed by ﬂow cytometry and
luminex.
Results: All patients had cGVHD of skin, liver and obstructive
bronchiolitis. Patients 1 and 2 are regarded as partial re-
sponders (PR) and patient 3 as a non-responder (NR).
Response was evaluated according to the NIH guidelines for
diagnosing cGvHD.
Patients receiving 111In-DSCs showed the same distribu-
tion pattern of the isotope over time. The isotopewas initially
located in the lungs, followed by dissemination to liver and
spleen.
The ﬂow cytometry and luminex data are presented as the
median frequency of data from all time points for each pa-
tient. Patient 3 had high frequencies of HLA-DR+ cells within
the CD3+CD4+ cell population (Th) (median 72.9%, range
72.7-73.3%). The corresponding proportions in patients 1 and
2 were 21.5% (17.6-21.9) and 36.5% (25.8-50-8), respectively.
Among CD3+CD8+cells (Tc), the frequency of HLA-DR-
expression was 33.6% (30.9-37.5), 60.5% (56.7-68.1) and
80.6% (70.8-83.8) for patient 1, 2, and 3, respectively.
The percentage of Th-cells with a naïve (CD45RA+CCR7+)
phenotype was 4.8% (3.6-6.3) in patient 3, but 24.4% (4.3-
24.4) and 25.1% (11.2-26.3) in patient 1 and 2, respectively.
The proportion of terminally differentiated (CD45RA-CCR7+)
Th-cells was 2.3% (2.1-2.6), 7.4% (2.4-8.7) and 12.7% (10.9-
23.2) in patients 1, 2, and 3, respectively.
The frequency of Tregs (CD4+CD25highCD127low/-) was
11.5% (8.63-15.9) for patient 3, whereas they were 6.4%
(4.8-6.5) and 3.3% (2.5-4.8) for patient 1 and 2, respectively.
Patient 3 had the highest proportion Th-cells with a
Th17 (CD45RA-CXCR3-CCR4+CCR6+), Th1/Th17 (CD45RA-
CXCR3+CCR4-CCR6+) and Th2 phenotype (CD45RA-CCR4+
CXCR3-CCR6-). Patient 3 also had the highest median plasma
concentrations of IL-17, IL-4 and IFN-g.
Discussion: DSCs are safe to infuse with no adverse effects.
We determined how stromal cells are distributed in vivo
following infusion in a GvHD setting. The data also support
that the non-responder had a more activated/exhausted
immune system than the partial responders. This study may
provide a basis for further controlled investigations into use
of DSCs as a treatment for severe cGvHD.172
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Peripheral blood progenitor cell collection (PBPC) is a routine
procedure in auto-HCT recipient and allo-HCT donors.
Spectra Optia is a next generation apheresis platform
following Cobe Spectra. Increasing the efﬁciency of PBPC
